David Meek
Chairman chez ENTASIS THERAPEUTICS HOLDINGS INC.
Fortune : 63 341 $ au 31/03/2024
Profil
David Meek a été nommé Directeur général d’Ipsen en juillet 2016. Il siège également au conseil d’administration du Groupe.
ll quittera le Conseil d'administration du groupe biopharmaceutique à compter du 31 décembre 2019 pour rejoindre FerGene en qualité de PDG.
David a une expérience de plus de 25 ans dans l’industrie pharmaceutique où il a occupé diverses fonctions de Direction au niveau global au sein de grands groupes pharmaceutiques et sociétés de biotechnologie. Avant de rejoindre Ipsen, David était Vice-Président Exécutif et Président de la division oncologie du laboratoire Baxalta.
Sa carrière en biopharmacie a démarré chez Johnson & Johnson et Janssen Pharmaceutica (1989-2004) où il a occupé des postes de direction des ventes et du marketing aux États-Unis, dans plusieurs domaines thérapeutiques en médecine générale, en médecine de spécialité et en oncologie.
David a ensuite rejoint Novartis (2005-2012), où il a successivement dirigé la franchise mondiale maladies respiratoires et dermatologie au siège à Bâle, en Suisse, puis la division pharmaceutique au Canada en qualité de Président-Directeur général, et enfin l’oncologie pour l’Europe du Nord, l’Europe de l’Est et l’Europe centrale. Entre 2012 et 2014, il a dirigé les opérations commerciales de la société de biotechnologie américaine Endocyte.
Avant d’entreprendre une carrière dans le secteur biopharmaceutique, David était officier dans l’armée américaine. Il est diplômé de l’Université de Cincinnati.
David siège aux conseils d’administration d’uniQure, PhRMA, EFPIA et de la Camping and Education Foundation.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
UNIQURE N.V.
0,03% | 15/09/2023 | 12 181 ( 0,03% ) | 63 341 $ | 31/03/2024 |
16/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Dernières actualités sur David Meek
Postes actifs de David Meek
Sociétés | Poste | Début |
---|---|---|
UNIQURE N.V. | Chairman | 16/06/2021 |
ENTASIS THERAPEUTICS HOLDINGS INC. | Chairman | 24/06/2019 |
FUSN PHAR | Director/Board Member | 16/10/2023 |
Camping & Education Foundation | Director/Board Member | - |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Director/Board Member | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Chairman | 24/06/2019 |
Anciens postes connus de David Meek
Sociétés | Poste | Fin |
---|---|---|
MIRATI THERAPEUTICS | Chief Executive Officer | 07/08/2023 |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Chief Executive Officer | 01/03/2021 |
IPSEN | Chief Executive Officer | 31/12/2019 |
░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de David Meek
University of Cincinnati (Ohio) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
IPSEN | Health Technology |
UNIQURE N.V. | Health Technology |
FUSN PHAR | Health Technology |
Entreprise privées | 14 |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Baxalta, Inc.
Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Endocyte, Inc.
Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Commercial Services |
Novartis Pharmaceuticals Canada, Inc.
Novartis Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Canada, Inc. manufactures chemicals and pharmaceuticals products. It provides solutions on patients suffering from a variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation, and osteoporosis. The company was founded in 1996 and is headquartered in Dorval, Canada. | Health Technology |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
Ipsen Manufacturing Ireland Ltd.
Ipsen Manufacturing Ireland Ltd. BiotechnologyHealth Technology Ipsen Manufacturing Ireland Ltd. operates as a biopharmaceutical group dedicated to improving lives through innovative medicines. The company was founded in 1989 and is headquartered in Dublin, Ireland. | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
Camping & Education Foundation |